Macrolide-resistant <i>Bordetella pertussis</i> strain identified during an ongoing epidemic, Finland, January to October 2024. [PDF]
Miettinen M +7 more
europepmc +1 more source
The effect of preexisting antibodies from Tdap vaccination during pregnancy on infant antibody responses to the pertussis-containing vaccines. [PDF]
Sereeyothin C +4 more
europepmc +1 more source
Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands. [PDF]
Gaasbeek CM +10 more
europepmc +1 more source
Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections. [PDF]
Da Costa RM +4 more
europepmc +1 more source
Mechanisms of natural and vaccine-induced immunity to Bordetella pertussis. [PDF]
Borkner L +4 more
europepmc +1 more source
SeaB is a conserved <i>Salmonella enterica</i> extracellular matrix binding protein involved in biofilm formation and infection. [PDF]
Da Costa RM +9 more
europepmc +1 more source
Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024. [PDF]
Rodrigues C +12 more
europepmc +1 more source
A BcfA-containing intranasal vaccine generated T<sub>H</sub>17 immunity and reduced B. bronchiseptica colonization and disease in mice. [PDF]
Aubrey AR +9 more
europepmc +1 more source
Variability in Vaccine Response and Trajectory in Early Childhood and Association With Demographic Variables, Antibiotic Exposure, and Infection Proneness. [PDF]
Pichichero ME +4 more
europepmc +1 more source
Pertussis Outbreak During 2023 in Gipuzkoa, North Spain. [PDF]
Marimón JM +7 more
europepmc +1 more source

